Acute Ph-negative lymphoblastic leukemias in adults: Risk factors in the use of the ALL-2009 protocol


Cite item

Full Text

Abstract

Aim. To analyze well-known risk factors (RFs), such as age, immunophenotype, baseline leukocytosis, enhanced lactate dehydrogenase (LDH) activity, time to achieve complete remission, a risk group, and cytogenetic abnormalities) in patients with acute lymphoblastic leukemia (ALL) in the use of the ALL-2009 protocol. Subjects and methods. The protocol covered 298 patients (137 women (including 13 pregnant women) and 161 men) aged 15 to 55 years (median age 28 years) with Ph-negative ALL. The phenotype was unknown in 6 patients. Three (1%) were ascertained to have a biphenotypic variant. 182 (62.4%) patients were found to have B-cell ALL (early pre-B ALL (n=51); common ALL (n=92), and pre-B ALL (n=39); 107 (36.6%) patients had T-cell ALL (early T-ALL (n=56); thymic T-ALL (n=41), and mature T-ALL (n=10). According to the baseline clinical and laboratory parameters (leukocytosis of 30·109/l and more for B-ALL; and that of 100·109/l and more for T-ALL; phenotype В-I for B-ALL, phenotype Т-I-II-IV for T-ALL; LDH activity was more than twice the normal values; the presence of translocation t(4;11)), the high-risk group included most patients with B-ALL (n=110 (72.8%)) and T-ALL (n=76 (76%)). Thirty-five patients with T-ALL underwent autologous bone marrow transplantation (BMT). Allogeneic BMT was performed in 18 (7%) of the 258 patients who had undergone an induction phase. Results. Five-year overall survival for all the patients included in the investigation was 59%; relapse-free survival was 65%, which was significantly different in the patients with B-ALL and in those with T-ALL: the overall survival rates were 53.3 and 67.5% (p=0.1); the relapse-free survival was 56 and 79% (p=0.005), respectively. Multivariate analysis including the well-known RFs demonstrated that the latter for T-ALL were of no independent prognostic value and only the patient’s age was identified for B-ALL (p=0.013). Conclusion. A lower chemotherapeutic load and a small number of allogeneic BMTs did not affect total positive treatment results in adult patients with ALL, by complying with the principle achieving the continuity of cytostatic effects and by preserving the total cytostatic loading dose. The results of the Russian investigation casts some doubt on the necessity of using very intensive consolidation cycles and performing a large number of allogeneic BMTs in adult patients with ALL.

References

  1. Recommendations of the European working group for adult ALL. Editor in chief N. Goekbuget. UNI-MED Verlag AG, Kurfurstenallee 130, D-28211 Bremen, German.
  2. Gökbuget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R, Fietkau R, Freund M, Ganser A, Ludwig WD, Maschmeyer G, Rieder H, Schwartz S, Serve H, Thiel E, Brüggemann M, Hoelzer D. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120:1868-1876. doi: 10.1182/blood-2011-09-377713
  3. Kheira Beldjord, Sylvie Chevret, Vahid Asnafi, et al Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123:3739-3749. doi:http://dx.doi.org/10.1182/blood-2014-01-547695.
  4. Kantarjian H, Thomas D, O’Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ. Long-Term Follow-Up Results of Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper-CVAD), a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia. Cancer. 2004;101(12):2788-2801. doi: 10.1002/cncr.20668
  5. Goldstone AH, Richards SM, Lazarus HM, Martin S. Tallman, Georgina Buck, Adele K. Fielding,Alan K. Burnett, Raj Chopra, Peter H. Wiernik, Letizia Foroni, Elisabeth Paietta, Mark R. Litzow, David I. Marks,Jill Durrant, Andrew McMillan, Ian M. Franklin, Selina Luger, Niculae Ciobanu, and Jacob M. Rowe. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111(4):1827-1833. doi:http://dx.doi.org/10.1182/blood-2007-10-116582
  6. Паровичникова Е.Н., Клясова Г.А., Исаев В.Г., Соколов А.Н., Кохно А.В., Троицкая В.В., Маврина Е.В., Ходунова Е.Е., Устинова Е.Н., Грибанова Е.О., Кравченко С.К., Рыжко В.В., Капорская Т.С., Баранова О.Ю., Бондаренко С.Н., А.С.Низаметдинова, Кондакова Е.В., Рыльцова Т.В., Алуферьева А.Н., Самойлова О.С., Скаморина О.П., Гаврилова Л.В., Приступа А.С., Вопилина Н.А., Константинова Т.С., Крючкова И.В., Анчукова Л.В., Тикунова Т.С., Капланов К.Д., Лапин В.А., Тумаков В.А., Козмина М.Н., Черныш С.А., Подольцева Э.И., Куликов С.М., Давидян Ю.Р., Савченко В.Г. Первые итоги терапии Ph-негативных острых лимфобластных лейкозов взрослых по протоколу Научно-исследовательской группы гематологических центров России ОЛЛ-2009. Терапевтический архив. 2011;7:11-17.
  7. Паровичникова Е.Н., Троицкая В.В., Соколов А.Н., Ахмерзаева З.Х., Кузьмина Л.А., Менделеева Л.П., Клясова Г.А., Кравченко С.К., Грибанова Е.О., Бондаренко С.Н., Баранова О.Ю., Капорская Т.С., Рыльцова Т.В., Низамутдинова А.С., Загоскина Т.П., Зинина Е.Е., Самойлова О.С., Климович А.В., Карякина Е.А., Елуферьева А.С., Гаврилова Л.В., Константинова Т.С., Лапин В.А., Приступа А.С., Вопилина Н.А., Тикунова Т.С., Скаморина О.П., Капланов К.Д., Обухова Т.Н., Гальцева И.В., Русинов М.А., Куликов С.М., СавченкоВ.Г. Промежуточные результаты по лечению острых Ph-негативных лимфобластных лейкозов (ОЛЛ) у взрослых больных (итоги Российской исследовательской группы по лечению ОЛЛ (RALL)). Онкогематология. 2014;3:6-15. doi: 10.17650/1818-8346-2014-9-3-6-15
  8. Troitskaya VV, Parovichnikova EN, Sokolov AN, Makhinya SA, Galstyan GM, Zvereva AV, Kliasova GA, Fidarova ZT, Gavrilina OA, Sidorova AA, Novikov SA, Kaporskaya TS, Lapin VA, Latyshkevich OA, Savchenko VG for the Russian ALL (RALL) study Group Pregnancy is not an exclusion criteria for the treatment according to the adults acute lymphoblastic leukemia protocol ALL-2009: results of the Russian ALL study group (RALL). Abstract book EHA, Jun 12, 2015; 102790, PB1604
  9. Nicola Gökbuget, Joachim Beck, Kalina Brandt, Monika Brüggemann, Thomas Burmeister, Helmut Diedrich, Christoph Faul, Andreas Hüttmann, Mustafa Kondakci, Doris M Kraemer, Oliver G Ottmann, Stefan Schwartz, Hubert Serve, Michael Starck, Matthias Stelljes, Reingard Stuhlmann, Andreas Viardot, Ralph M. Waesch, Knut Wendelin, Dietrich Beelen, Renate Arnold and Dieter Hoelzer. Significant Improvement Of Outcome In Adolescents and Young adults (AYAs) Aged 15-35 Years With Acute Lymphoblastic Leukemia (ALL) With a Pediatric Derived Adult ALL Protocol; Results Of 1529 AYAs In 2 Consecutive Trials Of The German Multicenter Study Group For Adult ALL (GMALL) Blood. 2013;122(21):839-839. doi:http://dx.doi.org/
  10. Rowe JM, Buck G, Burnett AK et al. Induction therapy for adults with acute lymphoblastic leukemia :results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760-3767. doi: 10.1182/blood-2005-04-1623
  11. Josep-María Ribera, Albert Oriol, Concepción Bethencourt, Ricardo Parody, Jesús-María Hernández-Rivas, María-José Moreno, Eloy del Potro, Mar Tormo,Concepción Rivas, Joan Besalduch, Miguel-Ángel Sanz, Juan-José Ortega on behalf of PETHEMA Group. Comparison of intensive chemotherapy, allogeneic orautologous stem cell transplantation as post-remissiontreatment for adult atients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica. 2005;90:1346-1356. doi: 10.1200/JCO.2006.06.8312
  12. Dhédin N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V, Thomas X, Chevallier P, Nguyen S, Coiteux V, Bourhis JH, Hichri Y, Escoffre-Barbe M, Reman O, Graux C, Chalandon Y, Blaise D, Schanz U, Lhéritier V, Cahn JY, Dombret H, Ifrah N. Role of Allogeneic Stem Cell Transplantation in Adult Patients with Ph-NegativeAcute Lymphoblastic Leukemia. Blood First Edition Paper, prepublished online January 13, 2015. doi: 10.1182/blood-2014-09-599894
  13. Cornelissen JJ, van der Holt B, Verhoef GE, van’t Veer MB, van Oers MH, Schouten HC, Ossenkoppele G, Sonneveld P, Maertens J, van Marwijk Kooy M, Schaafsma MR, Wijermans PW, Biesma DH, Wittebol S, Voogt PJ, Baars JW, Zachée P, Verdonck LF, Löwenberg B, Dekker AW, on behalf of the Dutch-Belgian HOVON Cooperative Group. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood. 2009;113:1375-1382. doi: 10.1182/blood-2008-07-168625
  14. Richard A Larson, Richard K Dodge, C Patrick Burns, Edward J Lee, Richard M Stone, Philip Schulman, David Duggan, Frederick R Davey, Robert E Sobol, Stanley R Frankel, Arthur L Hooberman, Carol A Westbrook, Diane C Arthur, Stephen L George, Clara D Bloomfield, and Charles A Schiffer A Five-Drug Remission Induction Regimen With Intensive Consolidation for Adults With Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8811 Blood. 1995;85(8):2025-2037. doi:http://dx.doi.org
  15. Marks DI, Moorman AV, Chilton L, Paietta E, Enshaie A, DeWald G, Harrison CJ, Fielding AK, Foroni L, Goldstone AH, Litzow MR, Luger SM, McMillan AK, Racevskis J, Rowe JM, Tallman MS, Wiernik P, Lazarus HM. The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. Haematologica. 2013;98(6): 945-952. doi: 10.3324/haematol.2012.081877
  16. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW, on behalf of the Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Adult Leukaemia Working Party of the United Kingdom and the Eastern Cooperative Oncology Group. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109:3189-3197. doi: 10.1182/blood-2006-10-051912

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies